Following a full submission
AWMSG advice |
||
| Status: Superseded | ||
AWMSG ADVICE SUPERSEDED BY NICE GUIDANCE ISSUED JANUARY 2016 & JUNE 2021. Refer to TA375: Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed and TA715: Adalimumab, etanercept, infliximab and abatacept for treating moderate rheumatoid arthritis after conventional DMARDs have failed for full guidance on NICE recommendations, including any specific restrictions on the use of the technology. AWMSG documentation provided for reference only. |
||
|
||
Medicine details |
||
| Medicine name | adalimumab (Humira®) | |
| Formulation | 40 mg solution for injection | |
| Reference number | 5 | |
| Indication | Treatment of moderate to severe, active rheumatoid arthritis in adult patients when the response to disease-modifying anti-rheumatic drugs including methotrexate has been inadequate |
|
| Company | AbbVie Ltd | |
| BNF chapter | Musculoskeletal & joint diseases | |
| Assessment type | Full | |
| Status | Superseded | |
| AWMSG meeting date | 02/12/2003 | |
| Ratification by Welsh Government | 01/03/2004 | |
| Date of issue | 31/03/2004 | |
| NICE guidance | ||